<DOC>
	<DOC>NCT02792504</DOC>
	<brief_summary>To evaluate safety and efficacy of CE/BZA in real practice in Korea</brief_summary>
	<brief_title>Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive</brief_title>
	<detailed_description />
	<criteria>1. Severe post menopausal vasomotor symptoms with uterus 2. postmenopausal osteopenia Women with undiagnosed abnormal uterine bleeding Women with known, suspected, or past history of breast cancer Women with known or suspected estrogendependent neoplasia Women with active deep venous thrombosis, pulmonary embolism, or history of these conditions Women with active arterial thromboembolic disease (for example, stroke, myocardial infarction) or history of these conditions Women who are receiving progestin, estrogen, or estrogenagonists/antagonists Women with hypersensitivity (for example, anaphylaxis, angioedema) to estrogens, bazedoxifene, or any ingredients Women with known hepatic impairment or disease Women with known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders Pregnant women, women who may become pregnant, and nursing mothers Women with hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>